Compass Therapeutics, Inc.
CMPXCompass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology.
Table of contents
Earnings
Next report
Aug 10, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology. The company utilizes its scientific expertise in the relationship between angiogenesis and the immune system to design candidates that target critical biological pathways required for anti-tumor responses. Its core value proposition lies in advancing a pipeline of bispecific and monoclonal antibodies as both standalone and combination therapies for various solid tumors.
A clinical-stage developer of bispecific antibodies with a lead candidate in Phase 2/3 trials for biliary tract cancer.
Questions, answered.
- What is Compass Therapeutics, Inc.'s market cap?
- Compass Therapeutics, Inc. (CMPX) has a market capitalization of $374.6M and trades on NASDAQ.
- Who are Compass Therapeutics, Inc.'s competitors?
- Compass Therapeutics, Inc.'s key competitors include Merck & Co., Inc., Amgen, Inc., Jazz Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Compass Therapeutics, Inc. partner with?
- Compass Therapeutics, Inc.'s notable partners include ABL Bio, Inc., Handok Pharmaceuticals, Inc., Elpiscience Biopharmaceuticals Co., Limited, and others.
- What subsidiaries does Compass Therapeutics, Inc. have?
- Compass Therapeutics, Inc.'s subsidiaries include Trigr Therapeutics, Inc..
- Where is Compass Therapeutics, Inc. headquartered?
- Compass Therapeutics, Inc. is headquartered in United States of America and employs approximately 32 people. It has been publicly traded since 2020.